FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins.
The post Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval appeared first on MedCity News.
GPT-Red beat human red teamers on a prompt injection test
GPT-Red is an automated red-teaming model that OpenAI trains to find prompt injection weaknesses. It works the way a human red-teamer does. It sends a
